GlassScriptPhysician profile
Alexander Moldanado
NPI 1184617136
$2,107.49
in general payments reported to CMS, 2019-2025
21 companies · $23.06 in 2025
The $23.06 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $369 · 2021: $86.06 · 2022: $436 · 2023: $411 · 2024: $428 · 2025: $23.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $279.30 | 2019-2024 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $206.46 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $199.32 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $171.00 | 2019-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $170.92 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Pfizer INC. | $160.25 | 2019-2024 | |
| Sanofi Pasteur INC. | $127.03 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.79 | 2020-2022 | |
| Abbott Laboratories | $101.12 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $99.31 | 2022 | |
| Janssen Pharmaceuticals, INC | $91.35 | 2020-2022 | |
| Astellas Pharma US INC | $80.74 | 2023-2024 | Veozah, Myrbetriq |
| Amgen INC. | $71.13 | 2024 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $56.22 | 2019-2020 | |
| Gilead Sciences, INC. | $50.23 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $25.95 | 2023 | Austedo |
| Corium, LLC | $23.68 | 2022 | |
| Heartflow, INC. | $23.15 | 2020 | |
| Novavax INC | $21.71 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Indivior INC. | $17.83 | 2024 | Sublocade |
| Cranial Technologies, INC | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Moldanado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.